Eurobench.com

voda 7 september 2012 16:46

0

quote:
Sl€ut€l schreef op 7 september 2012 16:40:
Voda,sluiten we op de 0.017?????

Mmm, lastige vraag. Ik krijg geen goed beeld door in mijn kristallen bol.
Slot op 1.6 cent denk ik.

Casper4711 7 september 2012 16:51

0

quote:
voda schreef op 7 september 2012 16:46:
[...]
Mmm, lastige vraag. Ik krijg geen goed beeld door in mijn kristallen bol.
Slot op 1.6 cent denk ik.

Had vanmiddag toch aardig het gevoel dat het up wilde.Dacht dat jij dat ook wel een beetje kon zien in de bied en laat.
Zelf had ff het gevoel 0.017/0.018.

voda 7 september 2012 17:37

0

quote:
voda schreef op 7 september 2012 16:46:
[...]
Mmm, lastige vraag. Ik krijg geen goed beeld door in mijn kristallen bol.
Slot op 1.6 cent denk ik.

Ja, weer krijg ik gelijk. Slot op 1.6 cent. Ja, die Voda heeft er wel kijk op. :-)

Casper4711 7 september 2012 17:46

0

Volgens mij op 0.017 slot,krijg er wel kijk op :-)

voda 7 september 2012 17:47

0

quote:
Sl€ut€l schreef op 7 september 2012 17:46:
Volgens mij op 0.017 slot,krijg er wel kijk op :-)

Fonds: aand. Pharming Group
Beurs: Euronext Amsterdam

Laatste Volume Tijd
Laatste 0,016 111.774 17:35:03
Verschil 0,001 6,6667 %
Bied 0,016 1.978.176 17:39:18
Laat 0,017 7.018.645 17:35:14
Hoogste 0,017 15:53:07
Laagste 0,015 09:00:02
Cum. volume --- 10.715.533
Indicatieve opening ---
Open 0,015 09:00:02
Vorig slot 0,015 06-09-2012
Gemiddelde dagomzet --- 8.210.591

PS:

www.youtube.com/watch?v=eqyUAtzS_6M

^___^:-)

[verwijderd] 10 september 2012 11:54

0

FDA approves new orphan drug for chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

An estimated 5,430 men and women will be diagnosed with CML in 2012. Most people with CML have a genetic mutation, called the Philadelphia chromosome, which causes the bone marrow to make an enzyme called tyrosine kinase. This enzyme triggers the development of too many abnormal and unhealthy white blood cells called granulocytes. Granulocytes fight infection.

Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib. Bosulif works by blocking the signal of the tyrosine kinase that promotes the development of abnormal and unhealthy granulocytes.

“With the approval of tyrosine kinase inhibitors, we are seeing improvements in the treatment of CML based on a better understanding of the molecular basis of the disease,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “These improvements have been observed in chronic and accelerated phases of CML.”

Other drugs recently approved by FDA to treat various forms of CML include imatinib (2001), dasatinib (2006) and nilotinib (2007).

The safety and effectiveness of Bosulif was evaluated in a single clinical trial that enrolled 546 adult patients who had chronic, accelerated or blast phase CML. All patients had disease that progressed after treatment with imatinib or imatinib followed by dasatinib and/or nilotinib, or who could not tolerate the side effects of prior therapy. All patients in the trial were treated with Bosulif.

In patients with chronic phase CML, efficacy was determined by the number of patients who experienced a major cytogenetic response (MCyR) within the first 24 weeks of treatment. Results showed 34 percent of patients who had been previously treated with imatinib achieved MCyR after 24 weeks. Of the patients who achieved MCyR at any time, 52.8 percent had their response last at least 18 months. Among patients previously treated with imatinib followed by dasatinib and/or nilotinib, about 27 percent achieved MCyR within the first 24 weeks of treatment. Of those who achieved MCyR at any time, 51.4 percent had their MCyR last at least nine months.

In patients with accelerated CML previously treated with at least imatinib, 33 percent had their blood counts that returned to normal range (complete hematologic response) and 55 percent achieved normal blood counts with no evidence of leukemia (overall hematologic response) within the first 48 weeks of treatment. Meanwhile, 15 percent and 28 percent of patients with blast phase CML achieved complete hematologic response and overall hematologic response, respectively.

The most common side effects observed in those receiving Bosulif were diarrhea, nausea, a low level of platelets in the blood (thrombocytopenia), vomiting, abdominal pain, rash, low red blood cell count (anemia), fever and fatigue.

Bosulif is marketed by New York City-based Pfizer.

BASF en BAYER kopen 10 september 2012 12:02

0

Bij de opening van dit draadje stond de de koers van Pharming op € 2,58 nu € 0,017

Casper4711 10 september 2012 14:36

0

Update Santarus.10/09

Piper Jaffray raised its rating on Santarus (NASDAQ: SNTS[FREE Stock Trend Analysis]) from Neutral to Overweight and increased a price target from $7 to $10.

Piper Jaffray noted, "With last week's appellate court ruling on Zegerid and the exit of the Par generic from the Zegerid market, visibility on meaningful cash generation has improved significantly. With net cash likely to approach $200M by 2H14 (with a market cap of only around $500M) and limited risk of generics on top seller Glumetza and Zegerid prior to 2016, we believe SNTS shares are attractive (2013 and 2014 P/E's of 9x and 7x, respectively) even with the recent strength."

Santarus closed at $7.48 on Friday.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read more: www.benzinga.com/analyst-ratings/anal...

[verwijderd] 11 september 2012 14:49

0

Protein Sciences announces presentations at ICAAC of clinical data on FluBlok®, the first recombinant egg - and additive free protection from influenza, by John Treanor, MD (pandemic formulation) and Lisa M. Dunkle, MD (seasonal formulation)

MERIDEN, Conn., Sept. 10, 2012 /PRNewswire/ -- Protein Sciences Corporation announced that this afternoon there will be a presentation of clinical data for the pandemic (monovalent) formulation of Protein Sciences innovative solution for protection from influenza, FluBlok, by John Treanor, MD, Chief of the Infectious Diseases Division of the Department of Medicine at the University of Rochester Medical Center. The presentation will occur at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Entitled "Safety and Immunogenicity of a Recombinant Hemagglutinin (rHA) Pandemic H5N1 Influenza Vaccine", the presentation will occur in Session 114 – Vaccines: Innovations, Impact and Safety at 3:00 pm in Room 121 of the Moscone Center in San Francisco.

FluBlok has been developed by Protein Sciences and is made using modern recombinant technology. It is highly purified, sterile and non-infectious and does not contain egg or other extraneous proteins, preservatives (such as Thimerosal) or antibiotics. Protein Sciences anticipates that FluBlok will receive FDA approval in the next few months and, if that occurs, it will have a limited number of doses available during the 2012-2013 influenza season.

Protein Sciences also announced that Lisa M. Dunkle, MD, Chief Medical Officer and Daniel Adams, Executive Chairman of Protein Sciences will present Phase III clinical data of the seasonal (trivalent, non-adjuvanted) formulation of FluBlok at 11:30 am on Tuesday, September 11 in the Product Theater Room in the Exhibit Area at ICAAC. Lunch will be served to early arrivals. More information can be obtained at the Protein Sciences booth No. 1420.

Protein Sciences further announced that Protein Sciences Europa, the European affiliate of Protein Sciences received acceptance from the European Medicines Agency of its Pediatric Investigative Plan for FluBlok. This approval sets the stage for submission of a regulatory filing for licensure of FluBlok in the European Union (E.U.). Protein Sciences Europa anticipates applying for E.U. approval early in 2013.

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most. BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

Our lead product, FluBlok, is a recombinant trivalent vaccine for seasonal influenza, consisting of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using cell culture instead of eggs. FluBlok is highly purified, does not include thimerosal or antibiotics, and is low in endotoxins. FluBlok, which has shown exceptional performance in clinical trials, is under final review by the U.S. Food and Drug Administration.

In 2009, we received a $147 million five-year contract award by the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services, to further develop our technology for the production of recombinant influenza vaccines for pandemic preparedness. Budgets totaling more than $80 million have thus far been approved to support work through at least mid-2013.

[verwijderd] 11 september 2012 15:12

0

Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia

LONDON and MOSCOW, September 11, 2012 /PRNewswire/ --

Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide

Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous administration. The results of these trials are of great importance as these novel long-acting, subcutaneous blood factors are expected to revolutionise the treatment paradigm for haemophilia sufferers worldwide. The availability of PBB's subcutaneous blood factors would make self-administration by patients at home much easier leading to a significant improvement in treatment compliance and reduction in healthcare system costs by avoiding the need for regular IV infusions.

Key findings from the 8 trials with 6 products conducted at the University of Alabama were:

PBB's current subcutaneous form of FVIIa achieved up to 3 days of haemostatic cover providing the prospect of sustained prophylactic treatment for haemophilia A patients who suffer an immune response to FVIII meaning that FVIII is no longer a viable therapy for them.
PBB's current intravenous form of Factor VIIa achieved a 12x extension of haemostasis over current commercially available products. This means it could offer significant advantages in trauma applications in hospitals where haemostatic cover can be maintained for the duration of long operations and post-operation, without the current need for multiple administrations and related complications.
PBB's subcutaneous form of Factor VIII for haemophilia A achieved a circulating dose level of 20% of the intravenous version and also maintained haemostasis for 72 hours, meaning that it is already suitable for twice-weekly dosing and will be able to be administered at higher subcutaneous doses enabling once weekly dosing or better.
PBB's subcutaneous form of FIX for haemophilia B maintained haemostasis for 10 days meaning that it is already suitable for dosing less frequently than once per week.
PBB expects to optimise these products so that each one will provide haemostatic cover for at least a week and possibly two weeks from a single subcutaneous injection (with circulating blood factor maximum dose levels ("Cmax") in line with the Malmo Protocol).

Following these successful trials PBB now has 6 blood factor products under development of which 3 can be administered subcutaneously and 3 by intravenous ("IV") injection. Each of these blood factor products has proven efficacy in a sophisticated combination of in vivo trials in naturally haemophiliac subjects and in vitro assays. PBB's novel improved blood factors utilise the epitope-cloaking property of PEG to prevent the products from being rapidly detected and destroyed by the patient's own immune system before the product has had a chance to fulfil its therapeutic potential. This property has already been demonstrated by PBB in a haemophilia B dog. Work is underway to demonstrate that PBB's other blood factor products are similarly "immune-silent".

PBB intends to optimise these products, confident that effective prophylactic cover will now be possible with each of these blood factors via a once-a-week regimen of shallow subcutaneous injections.

Professor Ted Tuddenham, emeritus Professor of Haemophilia at University College London and former Director of the Haemophilia Centre at the Royal Free Hospital, a pioneer in the development of gene therapy treatments for haemophilia commented "I consider these products to be a vital breakthrough by PBB as the availability of subcutaneous and long acting blood factors will dramatically improve the quality of life and treatment regimes for haemophilia sufferers. There is a clear and present need for these products, which in the longer term, will continue to augment potential gene therapy options."

John Mayo, CEO of PBB said, "This is great news. These new, improved blood factors have the potential to revolutionise the quality of life for haemophilia sufferers. These new products also have huge commercial potential. It is medically, morally and commercially important that these products get to market as quickly as possible."

[verwijderd] 11 september 2012 15:13

0

Further Information

Overview of PBB's blood factor technology

PBB has been able to generate these improved blood factors that retain their efficacy and have a longer half life while being capable of subcutaneous administration by attaching an inert molecule of polyethylene glycol ("PEG") to each individual blood factor molecule in a precise location remote from the active site on each blood factor. PBB's technology has been applied and tested successfully on several recombinant and plasma sourced blood factor proteins.

PBB has enhanced the performance of blood factors by pioneering the PEGylation of these proteins with TheraPEG™ technology, developed independently by Polytherics Ltd.
The recombinant human protein molecules are conjugated to a polyethylene glycol ("PEG") molecule. TheraPEG™ technology is uniquely successful where previous attempts to PEGylate blood factors have failed, by carefully locating PEG remotely from the active site on each protein, and by covering epitopes which otherwise trigger an immune response.
The careful individual pegylation of each molecule ensures that, molecule by molecule, the blood factors are made more water soluble. This enables subcutaneous delivery and allows the products to be formulated with less polysorbate, reducing the total amount of polyethylene glycol administered to a patient (when compared to conventional prophylaxis).
PBB has substantial intellectual property around these products, including exclusive global licences to TheraPEG™ in relation to these blood factors, in addition to PBB's own patents.

Summary observations from PBB's blood factor trials

Subcutaneous delivery

PBB achieved a world first in correcting the whole-blood clotting times of naturally haemophilic dogs to normal via a low-volume subcutaneous injection. As expected, unmodified proteins that were administered subcutaneously in the same studies (and at equivalent dose levels) were ineffective in providing haemostatic cover.

Naked Expected PBB protein PBB protein Extension of Protein Blood Haemostatic Haemostatic duration of Haemostatic Subcutaneous Factor cover (i) cover (i) Haemostasis Cover Bioavailability FVIIa 0 hrs 72 hrs --lemniscate 168+ hrs 89% FVIII 0 hrs 72 hrs --lemniscate 168+ hrs 40% (ii) FIX 0 hrs 240 hrs --lemniscate 336 hrs 86%

(i) The duration of "cover" is the time over which a whole blood clotting time of less than 12 minutes could be maintained

(ii) FVIII bioavailability figure reflects a minimum measurement (based on assays for the existing native protein) that is expected to improve as PBB develops specific assays for the new, improved protein.

Further extensions in duration of cover with the subcutaneous products are confidently expected since the Cmax of the subcutaneous products is significantly lower than for the intravenous products, providing plenty of scope for safe dose increases and further product optimisation.

[verwijderd] 11 september 2012 15:13

0

Intravenous delivery

Long-acting intravenous products are ideal for trauma applications including surgical and post-surgical treatment. PBB's modified blood factors clearly outperformed the currently available products (naked protein) in all trials.

Current PBB Expected PBB Naked protein protein Extension of Protein Blood Haemostatic Haemostatic duration of Haemostatic Factor cover (i) cover (i) Haemostasis Cover FVIIa 8 hrs 96hrs 12x 168 hrs FVIII 24 hrs 96 hrs 4x 168 hrs FIX 72 hrs 240 hrs 3x 336 hrs

(i) The duration of "cover" is the time over which a whole blood clotting time of less than 12 minutes could be maintained

PBB is confident that with regular product optimisation normal haemostatic cover of at least one week will be achieved for all 3 blood factors, both intravenously and subcutaneously.

These improved blood factors make possible, for the first-time, a subcutaneous, long-acting prophylactic regime that would lead to substantial improvements to the quality of life for haemophiliacs. Ease of administration, easier home use and a more convenient dosing regimen will result in improved compliance, thereby reducing the occurrence of micro-bleeds into the joints (leading to premature joint degradation), avoidance of vascular damage by high-volume intravenous dosage and a smoother and more consistent plasma concentration profile, giving a better prediction of the therapeutic benefit of these factors over time, benefitting patients and caregivers alike.

Notes to Editors

About Pro Bono Bio Group plc

Pro Bono Bio Group plc ("PBB") is an international healthcare company, which partners with leading scientists, eminent physicians and specialist service providers, to ensure we have access to the best talent available to develop products that target key unmet medical needs. PBB's approach is designed to create and bring to market important new therapies which will improve the lives of patients worldwide.

Pro Bono Bio launched its first medicine, FLEXISEQ™ for the treatment of pain associated with osteoarthritis in 2012 in Germany. Dermatology products, ROSSOSEQ and EXOSEQ, are scheduled to launch later this year.

About Haemophilia

Haemophilia A is the genetic disorder which causes an absence of the naturally occurring blood Factor VIII. Protein replacement therapy can be prophylactic (75%+ of patients in Western markets) or in response to bleeding events (greater in developing markets). The value of the global market for Factor VIII products in 2010 was circa $5bn.

Haemophilia B is the genetic disorder which causes an absence of the naturally occurring blood Factor IX. Protein replacement therapy can be prophylactic (75%+ of patients in Western markets) or event-driven (greater in developing markets). The value of the global market for Factor IX products in 2010 was circa $1bn.

Factor VIIa is needed as a substitute for Factor VIII when some (circa 30% of) haemophilia A patients develop an immune response to injected Factor VIII, thereby limiting its effectiveness. It is also used for the acute treatment of bleeding associated with major trauma and in some surgical settings. The value of the global FVIIa market in 2010 was estimated at circa $1.6bn.

[verwijderd] 12 september 2012 09:32

0

Santarus, Inc. (NASDAQ: SNTS) today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX®, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers’ diarrhea.

In the intent-to-treat (ITT) population (n=264), the median TLUS was 46.0 hours for rifamycin SV MMX (n=199) compared with 68.0 hours for placebo (n=65), p = 0.0008. Results in the per protocol population (n=240) were similar to the ITT population.

Rifamycin SV MMX was generally well tolerated in this Phase III clinical study and the frequency of treatment emergent adverse events was similar to placebo. The most frequent treatment emergent adverse events experienced by = 2% of patients in either treatment group were: headache (8.0% in active arm and 9.2% in the placebo arm), diarrhea (5.0% in the active arm and 9.2% in the placebo arm), infectious diarrhea (5.0% in the active arm and 7.7% in the placebo arm), constipation (3.5% in the active arm and 1.5% in the placebo arm), amoebic dysentery (0% in the active arm and 3.1% in the placebo arm) and gastrointestinal infection (0% in the active arm versus 3.1% in the placebo arm). There were three patients who experienced serious adverse events, all of which were assessed by the investigator as not related to the study drug. One patient in the placebo group developed clostridium difficile colitis and two patients in the rifamycin SV MMX group experienced a total of three adverse events: neuroblastoma, abdominal pain and vomiting. Santarus expects additional data from this clinical study will be presented at an appropriate medical meeting in 2013.

Santarus licensed rights to develop and commercialize rifamycin SV MMX in the U.S. from Cosmo Technologies Limited. Dr. Falk Pharma GmbH, Cosmo’s European development partner, is conducting a second Phase III clinical study to evaluate the efficacy of rifamycin SV MMX versus ciprofloxacin with the primary endpoint of TLUS in patients with travelers’ diarrhea. This non-inferiority study is expected to enroll approximately 1,000 patients and to be completed in mid-2013. Assuming positive results in the second Phase III clinical study, Santarus and Dr. Falk plan to share the clinical data from their respective Phase III studies for inclusion in each company’s regulatory submissions.

“These favorable Phase III results in travelers’ diarrhea represent a significant positive milestone in the clinical development of rifamycin SV MMX for the U.S. market. Rifamycin SV is an investigational broad spectrum, non-systemic antibiotic that has been used for more than 20 years in Europe in both intravenous and intramuscular forms, but is considered a new chemical entity in the U.S.,” said Wendell Wierenga, Ph.D., executive vice president, research and development of Santarus. “As we wait for completion of the second ongoing Phase III study being conducted by Dr. Falk Pharma, we plan to assess our options to evaluate rifamycin SV MMX in other indications where a non-systemic antibiotic with a broad spectrum of activity may offer a clinical benefit.”

Read more: www.pharmiweb.com/pressreleases/press...

[verwijderd] 12 september 2012 17:39

1

Er is goed nieuws onderweg. Veel kopers ineens.
Langzaam kruipt Pharming omhoog.

De Witte Ruiter 12 september 2012 18:19

0

quote:
Blutter schreef op 12 september 2012 17:39:
Er is goed nieuws onderweg. Veel kopers ineens.
Langzaam kruipt Pharming omhoog.

Afronding van de studie zit er snel aan te komen, het is zeker mogelijk dat het rapport eind deze week of volgende week naar buiten word gebracht. Dan moet je niet raar opkijken als er die dag meer dan 100 miljoen aandelen worden verhandeld, dan is er een stijging van minimaal 50% mogelijk.

[verwijderd] 12 september 2012 18:22

0

quote:
protrek schreef op 12 september 2012 18:19:
[...]

Afronding van de studie zit er snel aan te komen, het is zeker mogelijk dat het rapport eind deze week of volgende week naar buiten word gebracht. Dan moet je niet raar opkijken als er die dag meer dan 100 miljoen aandelen worden verhandeld, dan is er een stijging van minimaal 50% mogelijk.

Ja, dat denk ik ook. Wat koop je tegenwoordig nog voor 4 cent.

[verwijderd] 13 september 2012 15:09

0

Published Preclinical Data Demonstrate Ability of Gliknik's Recombinant Stradomers™ to Mimic Anti-Autoimmune Effect of IVIG

- Recombinant Product May Have Advantages for Treating Patients with a Variety of Autoimmune Diseases and Disorders Who Currently Receive Pooled Human Blood Product, IVIG -

BALTIMORE, Sept. 12, 2012 /PRNewswire/ -- Gliknik Inc., a biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that its stradomers™ have clinical therapeutic potential, based upon newly published preclinical data in models of rheumatoid arthritis and thrombocytopenia (blood platelet deficiency). The research, which is part of a collaboration with the lab of Professor Scott Strome at the University of Maryland, Baltimore, was electronically published August 20, 2012 in Arthritis Research and Therapy.

Stradomers™ are recombinant drugs designed to mimic the efficacy of a well-known marketed drug, IVIG, a blood-derived product used clinically in more than 50 autoimmune diseases. IVIG contains antibodies gathered from tens of thousands of people and includes a small percent of antibody aggregates. Stradomers™ are pure, laboratory-made clusters of the Fc portion of human antibodies. Gliknik and University of Maryland scientists believe that such Fc aggregates and Fc clusters are responsible for much of the biological activity of IVIG and of stradomers™ in autoimmune diseases.

Importantly, stradomer™ Fc clusters are designed to bind extremely well to immune cell receptors in comparison with individual immunoglobulin Fc found on monoclonal antibodies. As a result, they may have higher potency in the treatment of autoimmune diseases and disorders. Because stradomers™ are laboratory made, whereas IVIG is produced from processed human blood pooled from many human donors, stradomers™ also have supply advantages versus IVIG.

"Our preclinical research results improve our understanding of the role stradomers™ may play in treating autoimmune diseases and highlight the importance of the binding of Fc clusters to immune cells in autoimmune disorders," said David S. Block, Gliknik President & Chief Executive Officer. "These findings support the further development of stradomers™ in clinical trials." Gliknik is currently advancing its lead stradomer™ candidate, GL-2045, into contract manufacturing for clinical studies scheduled to begin in late 2013.

[verwijderd] 14 september 2012 16:36

0

www.sobi.com/en/Investors--Media/News...

[verwijderd] 15 september 2012 07:24

0

hm... www.nu.nl/binnenland/2910217/cvz-legt...

Casper4711 15 september 2012 21:28

0

za 15 sep 2012, 19:49 |lees voor
Alarm artsen vergoeding medicijn spierziekte AMSTERDAM - Een aantal gerenommeerde artsen slaat alarm over het voornemen de vergoeding te stoppen van een medicijn tegen de ziekte van Pompe. Namens het ISNO, het Interuniversitair Steunpunt Neuromusculair Onderzoek, hebben de artsen een brief gestuurd aan het College voor zorgverzekeringen (CVZ) waarin ze schrijven dat ze vrezen voor de toekomst van nieuwe behandelingen van zeldzame spierziekten.
Neuroloog Jan Verschuuren zei dat zaterdagavond.

De afgelopen tijd is al veel te doen geweest om de prijs van medicijnen. Het CVZ stelde dat dure geneesmiddelen voor de ziekten van Pompe en Fabry niet langer vergoed moeten worden. Dit omdat de prijs niet opweegt tegen de gezondheidswinst. Daarop werd onder meer in de Tweede Kamer en bij patiëntenverenigingen al kritisch gereageerd.

Verschuuren c.s. -„wij behandelen en zien die patiënten toch” - zijn bang dat (de ontwikkeling van) andere medicijnen hiermee ook ter discussie komt te staan. „Mogelijk worden ontwikkelaars ervan zelfs minder enthousiast voor verder onderzoek, als het toch niet vergoed wordt.”

In 2000 is er onderzoek geweest door Pharming.

PHARMING ONDER DRUK GESTOPT MET ONDERZOEK ZIEKTE VAN POMPE Het Leidse biotechnologiebedrijf Pharming is onder druk van zijn Amerikaanse partner Genzyme gestopt met de productie van transgene konijnenmelk (alfa-glucosidase) als medicijn tegen de ziekte van Pompe.

www.gezinuswolters.nl/PDFS/erasmusart...

Vertraagd	7 mrt 2025 17:35
Koers	0,758
Verschil	-0,012 (-1,49%)
Hoog	0,780
Laag	0,755
Volume	9.995.843
Volume gemiddeld	5.981.338
Volume gisteren	19.214.251

04 mrt	Groen licht voor nieuwe CEO Pharming
04 mrt	Rode koersenborden nu de mondiale han...
03 mrt	Groene futures, Trump praat crypto's ...
20 feb	Pharming heeft bijna 93% van Abliva i...	1
07 feb	Pharming verklaart bod op Abliva onvo...
21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming

Pharming « Terug naar discussie overzicht

Sectornieuws - biotech

Meedoen aan de discussie?

Direct naar Forum

Detail

Pharming nieuws